Sigilon Therapeutics Statistics
Share Statistics
Sigilon Therapeutics has 2.5M
shares outstanding. The number of shares has increased by 2.94%
in one year.
| Shares Outstanding | 2.5M |
| Shares Change (YoY) | 2.94% |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 27 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 8.23K, so 0.33% of the outstanding
shares have been sold short.
| Short Interest | 8.23K |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.48% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -3.39 and the forward
PE ratio is null.
Sigilon Therapeutics's PEG ratio is
0.04.
| PE Ratio | -3.39 |
| Forward PE | n/a |
| PS Ratio | 11.39 |
| Forward PS | n/a |
| PB Ratio | 3.77 |
| P/FCF Ratio | -2.83 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Sigilon Therapeutics has an Enterprise Value (EV) of 133.44M.
| EV / Sales | 10.31 |
| EV / EBITDA | -3.23 |
| EV / EBIT | -2.59 |
| EV / FCF | -2.57 |
Financial Position
The company has a current ratio of 2.4,
with a Debt / Equity ratio of 0.72.
| Current Ratio | 2.4 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | -0.68 |
| Debt / FCF | -0.54 |
| Interest Coverage | -19.07 |
Financial Efficiency
Return on Equity is -111.02% and Return on Invested Capital is -64.82%.
| Return on Equity | -111.02% |
| Return on Assets | -49.79% |
| Return on Invested Capital | -64.82% |
| Revenue Per Employee | $208,774.19 |
| Profits Per Employee | $-700,903.23 |
| Employee Count | 62 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -105K |
| Effective Tax Rate | 0.24% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 4.11, so Sigilon Therapeutics's
price volatility has been higher than the market average.
| Beta | 4.11 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 16.97 |
| 200-Day Moving Average | 10.29 |
| Relative Strength Index (RSI) | 71.26 |
| Average Volume (20 Days) | 120,683 |
Income Statement
In the last 12 months, Sigilon Therapeutics had revenue of 12.94M
and earned -43.46M
in profits. Earnings per share was -1.34.
| Revenue | 12.94M |
| Gross Profit | 12.94M |
| Operating Income | -43.67M |
| Net Income | -43.46M |
| EBITDA | -41.27M |
| EBIT | -41.27M |
| Earnings Per Share (EPS) | -1.34 |
Full Income StatementBalance Sheet
The company has 42.07M in cash and 28.06M in
debt, giving a net cash position of 14.01M.
| Cash & Cash Equivalents | 42.07M |
| Total Debt | 28.06M |
| Net Cash | 14.01M |
| Retained Earnings | -256.8M |
| Total Assets | 55.56M |
| Working Capital | 19.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -51.47M
and capital expenditures -537K, giving a free cash flow of -52.01M.
| Operating Cash Flow | -51.47M |
| Capital Expenditures | -537K |
| Free Cash Flow | -52.01M |
| FCF Per Share | -1.6 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -337.35% and -335.72%.
| Gross Margin | 100% |
| Operating Margin | -337.35% |
| Pretax Margin | -336.53% |
| Profit Margin | -335.72% |
| EBITDA Margin | -318.84% |
| EBIT Margin | -337.35% |
| FCF Margin | -401.82% |
